Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 421–430 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 421

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    CYP2C19
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      In a clinical study, concomitant administration of armodafinil 400 mg resulted in a 40% increase in exposure to omeprazole after a single oral dose (40 mg), as a result of moderate inhibition of CYP2C19 activity [see ] . • Interactions with CNS Active Drugs Concomitant administration of armodafinil with quetiapine reduced the systemic exposure of quetiapine.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      In a clinical study, concomitant administration of armodafinil 400 mg resulted in a 40% increase in exposure to omeprazole after a single oral dose (40 mg), as a result of moderate inhibition of CYP2C19 activity [see ] . • Interactions with CNS Active Drugs Concomitant administration of armodafinil with quetiapine reduced the systemic exposure of quetiapine.

  2. Projected row 422

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    CYP2C19
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      Drug Interactions In vitro data demonstrated that armodafinil weakly induces CYP1A2 and possibly CYP3A activities in a concentration-related manner and that CYP2C19 activity is reversibly inhibited by armodafinil.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      However, in a clinical study using caffeine as a probe substrate, no significant effect on CYP1A2 activity was observed. • Drugs Metabolized by CYP2C19 In vitro data demonstrated that armodafinil is a reversible inhibitor of CYP2C19 activity.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      Drug Interactions In vitro data demonstrated that armodafinil weakly induces CYP1A2 and possibly CYP3A activities in a concentration-related manner and that CYP2C19 activity is reversibly inhibited by armodafinil.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      However, in a clinical study using caffeine as a probe substrate, no significant effect on CYP1A2 activity was observed. • Drugs Metabolized by CYP2C19 In vitro data demonstrated that armodafinil is a reversible inhibitor of CYP2C19 activity.

  3. Projected row 423

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      However, due to the partial involvement of CYP3A enzymes in the metabolic elimination of armodafinil, coadministration of potent inducers of CYP3A4/5 (e.g., carbamazepine, phenobarbital, rifampin) or inhibitors of CYP3A4/5 (e.g., ketoconazole, erythromycin) could alter the plasma concentrations of armodafinil.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      The Potential of Armodafinil to Alter the Metabolism of Other Drugs by Enzyme Induction or Inhibition • Drugs Metabolized by CYP3A4/5 In vitro data demonstrated that armodafinil is a weak inducer of CYP3A activity in a concentration-related manner.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      However, due to the partial involvement of CYP3A enzymes in the metabolic elimination of armodafinil, coadministration of potent inducers of CYP3A4/5 (e.g., carbamazepine, phenobarbital, rifampin) or inhibitors of CYP3A4/5 (e.g., ketoconazole, erythromycin) could alter the plasma concentrations of armodafinil.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      The Potential of Armodafinil to Alter the Metabolism of Other Drugs by Enzyme Induction or Inhibition • Drugs Metabolized by CYP3A4/5 In vitro data demonstrated that armodafinil is a weak inducer of CYP3A activity in a concentration-related manner.

  4. Projected row 424

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      The impact of inhibition of P-glycoprotein is not known. • Interactions with Other Drugs Data specific to armodafinil drug-drug interaction potential for additional other drugs are not available.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      The impact of inhibition of P-glycoprotein is not known. • Interactions with Other Drugs Data specific to armodafinil drug-drug interaction potential for additional other drugs are not available.

  5. Projected row 425

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      Data specific to armodafinil or modafinil drug-drug interaction potential with monoamine oxidase (MAO) inhibitors are not available [see ]. • Interaction with P-Glycoprotein An in vitro study demonstrated that armodafinil is a substrate of P-glycoprotein.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      Data specific to armodafinil or modafinil drug-drug interaction potential with monoamine oxidase (MAO) inhibitors are not available [see ]. • Interaction with P-Glycoprotein An in vitro study demonstrated that armodafinil is a substrate of P-glycoprotein.

  6. Projected row 426

    Medicine slug
    armodafinil
    Medicine name
    Armodafinil
    Enzyme or transporter
    P-GLYCOPROTEIN
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      An in vitro study demonstrated that armodafinil is a substrate of P-glycoprotein.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:93b9f9a4-66d9-4ed9-8f2f-903e416e900d (opens source in a new tab)

      Armodafinil label

      Version not recorded · Effective date not recorded

      An in vitro study demonstrated that armodafinil is a substrate of P-glycoprotein.

  7. Projected row 427

    Medicine slug
    asciminib
    Medicine name
    Asciminib
    Enzyme or transporter
    BCRP
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Imatinib: The asciminib AUC inf and C max increase by 108% and 59%, respectively following coadministration of a single SCEMBLIX dose of 40 mg with imatinib (an inhibitor of BCRP, CYP3A4, UGT2B17, and UGT1A3/4).
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib inhibits BCRP, P-gp, OATP1B1, OATP1B3, and OCT1.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Imatinib: The asciminib AUC inf and C max increase by 108% and 59%, respectively following coadministration of a single SCEMBLIX dose of 40 mg with imatinib (an inhibitor of BCRP, CYP3A4, UGT2B17, and UGT1A3/4).
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib inhibits BCRP, P-gp, OATP1B1, OATP1B3, and OCT1.

  8. Projected row 428

    Medicine slug
    asciminib
    Medicine name
    Asciminib
    Enzyme or transporter
    BCRP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib is eliminated by biliary secretion via breast cancer-resistant protein (BCRP).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib is eliminated by biliary secretion via breast cancer-resistant protein (BCRP).

  9. Projected row 429

    Medicine slug
    asciminib
    Medicine name
    Asciminib
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Transporter Systems Asciminib is a substrate of BCRP and P-gp.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib may increase the exposure of BCRP substrates in a dose dependent manner.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Transporter Systems Asciminib is a substrate of BCRP and P-gp.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      Asciminib may increase the exposure of BCRP substrates in a dose dependent manner.

  10. Projected row 430

    Medicine slug
    asciminib
    Medicine name
    Asciminib
    Enzyme or transporter
    CYP2C19
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      In addition, asciminib may reversibly inhibit CYP2C19 at concentrations reached at 200 mg twice daily dose.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:e33001e7-3650-42b1-ae56-cddb5c43aa2b (opens source in a new tab)

      Asciminib label

      Version not recorded · Effective date not recorded

      In addition, asciminib may reversibly inhibit CYP2C19 at concentrations reached at 200 mg twice daily dose.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=420

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy